DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 🎓 Expert Commentary / Peer Perspective
Federal regulations currently permit telehealth stimulant prescribing for ADHD through December 2026, but state rules can impose additional requirements including mandatory in-person visits. NPs and PAs prescribing stimulants virtually must navigate both layers simultaneously to remain compliant.
Professional Impact
- State regulations can require in-person visits for initial evaluation or at defined intervals even when federal rules permit fully virtual prescribing
- Evidence-based diagnostic documentation, including rating scales or validated testing, provides a defensible record if prescribing decisions are ever challenged
- Patients aged 25 to 35 carry higher stimulant misuse risk in research literature, warranting heightened screening in this cohort
- PMP review can identify dose discrepancies and doctor shopping before prescribing or continuing stimulant therapy
Action Items
- Verify current state telehealth prescribing requirements independently of federal DEA guidance
- Document ADHD diagnosis with a validated screening tool or rating scale before initiating stimulants via telehealth
- Establish referral pathways for urine drug screening and EKG access through primary care partnerships
- Review PMP records at initiation and monitor for multi-provider prescribing patterns
